ロード中...
HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine
An important goal of human immunodeficiency virus (HIV) vaccine design is identification of strategies that elicit effective antiviral humoral immunity. One novel approach comprises priming with DNA and boosting with modified vaccinia virus Ankara (MVA) expressing HIV-1 Env on virus-like particles....
保存先:
| 出版年: | J Virol |
|---|---|
| 主要な著者: | , , , , , , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
American Society for Microbiology
2017
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5709589/ https://ncbi.nlm.nih.gov/pubmed/29021394 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/JVI.01077-17 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|